Last reviewed · How we verify

NCT07062016

Molecular and ctDNA Characterization of High-Risk Endometrial Cancer

Recruiting now Last updated 13 April 2026
What this trial tests

trial testing Non-Interventional Study in Endometrial Carcinoma in 100 participants. Currently enrolling.

Timeline
1 October 2025
Primary endpoint
31 October 2028
31 October 2028

Quick facts

Lead sponsorMayo Clinic
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment100
Start date1 October 2025
Primary completion31 October 2028
Estimated completion31 October 2028
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Mayo Clinic

Who can join

18 and older, female only, with Endometrial Carcinoma or Endometrial High Grade Endometrioid Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study seeks to better understand the recurrence of high-risk endometrial cancer. It will collect information about cancer genetics to find out various hereditary or cancer specific genetic variants that may have a role in diagnosis or management and prognosis of cancer. It also seeks to develop a genetic results and medical record databank for future studies.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Non-Interventional Study

Trials testing the same drug.

Other recruiting trials for Endometrial Carcinoma

Currently open trials in the same condition.

Other Mayo Clinic trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07062016.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing